The collapse of Christian Eriksen on the pitch during Euro 2020 was a stark reminder of the fragility of life, but also a testament to the value of medical preparedness. The implantable cardioverter-defibrillator (ICD) that now resides in his chest did not just save his life. It validated a protocol largely shaped by British medics, who have long championed the use of such devices in high-risk athletes.
In the aftermath, global sporting bodies scrambled to reassess their emergency response systems, with many adopting the UK’s model of on-site defibrillators and trained response teams. The cost of these devices is not trivial, but when stacked against the economic loss of a top-tier player, the net present value becomes strikingly clear. Capital markets took note, too.
Shares in device manufacturers like Medtronic and Boston Scientific saw a modest uptick, reflecting the insurance value such innovations provide. But the real bottom line here is human life, and the efficient deployment of medical resources. The UK’s National Health Service, often criticised for its budget constraints, can claim a moral victory in this instance.
The question remains, however, whether the rest of the world will follow suit or leave such life-saving infrastructure to the vagaries of market forces.
